Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy.
Shrestha N, Dee MJ, Chaturvedi P, Leclerc GM, Mathyer M, Dufour C, Arthur L, Becker-Hapak M, Foster M, McClain E, Pena NV, Kage K, Zhu X, George V, Liu B, Egan J, Echeverri C, Wang M, You L, Kong L, Li L, Berrien-Elliott MM, Cooper ML, Fehniger TA, Rhode PR, Wong HC. Shrestha N, et al. Among authors: rhode pr. Cancer Immunol Immunother. 2024 Jul 3;73(9):179. doi: 10.1007/s00262-024-03765-8. Cancer Immunol Immunother. 2024. PMID: 38960949 Free PMC article.
A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice.
Zhu X, Li Q, George V, Spanoudis C, Gilkes C, Shrestha N, Liu B, Kong L, You L, Echeverri C, Li L, Wang Z, Chaturvedi P, Muniz GJ, Egan JO, Rhode PR, Wong HC. Zhu X, et al. Among authors: rhode pr. Front Immunol. 2023 Jan 25;14:1114802. doi: 10.3389/fimmu.2023.1114802. eCollection 2023. Front Immunol. 2023. PMID: 36761778 Free PMC article.
Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice.
Shrestha N, Chaturvedi P, Zhu X, Dee MJ, George V, Janney C, Egan JO, Liu B, Foster M, Marsala L, Wong P, Cubitt CC, Foltz JA, Tran J, Schappe T, Hsiao K, Leclerc GM, You L, Echeverri C, Spanoudis C, Carvalho A, Kanakaraj L, Gilkes C, Encalada N, Kong L, Wang M, Fang B, Wang Z, Jiao JA, Muniz GJ, Jeng EK, Valdivieso N, Li L, Deth R, Berrien-Elliott MM, Fehniger TA, Rhode PR, Wong HC. Shrestha N, et al. Among authors: rhode pr. Aging Cell. 2023 May;22(5):e13806. doi: 10.1111/acel.13806. Epub 2023 Mar 26. Aging Cell. 2023. PMID: 36967480 Free PMC article.
Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.
Chaturvedi P, George V, Shrestha N, Wang M, Dee MJ, Zhu X, Liu B, Egan J, D'Eramo F, Spanoudis C, Gallo V, Echeverri C, You L, Kong L, Fang B, Jeng EK, Rhode PR, Wong HC. Chaturvedi P, et al. Among authors: rhode pr. Mol Ther. 2022 Mar 2;30(3):1171-1187. doi: 10.1016/j.ymthe.2022.01.025. Epub 2022 Jan 17. Mol Ther. 2022. PMID: 35051615 Free PMC article.
A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.
Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM, Marsala LI, Foster M, Schappe T, Tran J, Desai S, Neal CC, Pence P, Wong P, Wagner JA, Russler-Germain DA, Zhu X, Spanoudis CM, Gallo VL, Echeverri CA, Ramirez LL, You L, Egan JO, Rhode PR, Jiao JA, Muniz GJ, Jeng EK, Prendes CA, Sullivan RP, Berrien-Elliott MM, Wong HC, Fehniger TA. Becker-Hapak MK, et al. Among authors: rhode pr. Cancer Immunol Res. 2021 Sep;9(9):1071-1087. doi: 10.1158/2326-6066.CIR-20-1002. Epub 2021 Jul 9. Cancer Immunol Res. 2021. PMID: 34244297 Free PMC article.
Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors.
Liu B, Zhu X, Kong L, Wang M, Spanoudis C, Chaturvedi P, George V, Jiao JA, You L, Egan JO, Echeverri C, Gallo VL, Xing J, Ravelo K, Prendes C, Antolinez J, Denissova J, Muniz GJ, Jeng EK, Rhode PR, Wong HC. Liu B, et al. Among authors: rhode pr. Mol Ther. 2021 Oct 6;29(10):2949-2962. doi: 10.1016/j.ymthe.2021.06.001. Epub 2021 Jun 4. Mol Ther. 2021. PMID: 34091051 Free PMC article.
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS. Margolin K, et al. Among authors: rhode pr. Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25. Clin Cancer Res. 2018. PMID: 30045932 Free PMC article. Clinical Trial.
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP. Wrangle JM, et al. Among authors: rhode pr. Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5. Lancet Oncol. 2018. PMID: 29628312 Free PMC article. Clinical Trial.
34 results